Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Breast 3Thoracic 2Gastrointestinal 2Plasma cell 1NET 1Endocrine 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 80Leukemia, Myeloid, Acute 74Multiple Myeloma 70Breast Neoplasms 70Lymphoma, Non-Hodgkin 62Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 53Burkitt Lymphoma 52Recurrence 51Myelodysplastic Syndromes 50Lymphoma, Follicular 50Lymphoma, B-Cell 47Leukemia 43Triple Negative Breast Neoplasms 40Lymphoma, Mantle-Cell 38Neoplasms 37Hodgkin Disease 34Melanoma 33Lymphoma, B-Cell, Marginal Zone 32Hematologic Neoplasms 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Neuroblastoma 28Ovarian Neoplasms 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Neoplasm Metastasis 22Pancreatic Neoplasms 21Leukemia, Biphenotypic, Acute 21Sarcoma 18Myeloproliferative Disorders 17

Interventions

pembrolizumab 4Nivolumab 4fludarabine 3aldesleukin 3Ipilimumab 3Cyclophosphamide 3vedolizumab 2enfortumab vedotin 2darolutamide 2cabozantinib 2atezolizumab 2Specimen Handling 2Riluzole 2Prednisone 2Magnetic Resonance Spectroscopy 2LDP-02 2Infliximab 2Immunoglobulin G 2Fecal Microbiota Transplantation 2Disulfides 2CTLA-4 Antigen 2CT-P13 2Biopsy 2relatlimab 1prednylidene 1palbociclib 1olaparib 1gallium 68 PSMA-11 1deltacortene 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Cyclophosphamide × 1 year × Clear all
NCT01174121 2026-06-05

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
332 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT06253520 2026-05-08

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
210 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Ovarian Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡